EUVIMEDEUVIMED entdecken
Crossref

Individualized treatment effects of high flow nasal oxygen in immunocompromised patients

Alexis Maillard, Mélanie Métais, Virginie Lemiale, Djamel Mokart, Anne-Sophie Moreau, Emmanuel Canet, Achille Kouatchet, Kevin G Buell, Samir Jaber, Laurent Argaud, Florent Wallet, Frédéric Pène und 2 weitere

Intensive Care Medicine · 02.11.2026

DOI: 10.1007/s00134-026-08635-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intensive Care Medicine, online erschienen am 02.11.2026. Verfasst von Alexis Maillard und 13 weiteren Autor:innen. Beteiligte Einrichtung: Service de médecine intensive et réanimation, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris, Paris, France. alexis.maillard@aphp.fr. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

High flow nasal oxygen (HFNO) has become a common first-line practice for acute hypoxemic respiratory failure (ARF). In immunocompromised patients, ARF is the leading cause of ICU admission, yet a randomized trial found no overall benefit of HFNO in this population.

Objectives

To assess whether baseline characteristics influence HFNO’s effectiveness in preventing invasive mechanical ventilation (IMV) in immunocompromised patients with ARF.

Methods

A causal forest machine-learning algorithm was derived in the HIGH trial (776 patients randomized to HFNO or conventional oxygen) to predict the HFNO effects on day-28 IMV incidence. Patients with a “do-not-intubate” order ( n = 72) were excluded. Model performance was validated through 500 bootstrap iterations and patients were categorized into terciles based on predicted HFNO benefit. Transportability of the model was assessed in an independent observational cohort (818 patients). Main results Among the 704 participants, HFNO’s average effect on day-28 IMV was not significant. However, substantial heterogeneity in treatment responses was identified (predicted benefit: from 20.2% [IQR 15.5%–23.9%] absolute IMV risk reduction with HFNO to 7.4% risk reduction [2.9%–11.2%] with conventional oxygen). Patients with the highest predicted benefit were older, more frequently solid organ transplant recipients, less neutropenic, more severely hypoxemic/tachycardic, but with lower non-respiratory sequential organ failure assessment (SOFA) scores. In this subgroup, HFNO was associated with a significant lower incidence of IMV. In the observational cohort, the benefit-ranking performance was preserved, although absolute effect estimates were less calibrated.

Conclusions

These results suggest HFNO might benefit specific immunocompromised patients with ARF. Further prospective studies are needed to validate these findings Graphical Abstract

Schlagwörter

Stichwörter der Autor:innen

Noninvasive ventilationRespiratory insufficiencyVentilator weaning

Autor:innen und Institutionen

  • Service de médecine intensive et réanimation, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris, Paris, France. alexis.maillard@aphp.fr.
  • Service de médecine intensive et réanimation, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.
  • Département d'Anesthésie-Réanimation, Institut Paoli-Calmettes, Marseille, France.
  • Pôle de médecine intensive réanimation, Hôpital Roger Salengro, CHU Lille, Lille, France.
  • Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France.
  • Médecine intensive et réanimation, CHU d'Angers, Angers, France.

Förderung

  • Ministry of Health

Zitieren

APA

Maillard, A., Métais, M., Lemiale, V., Mokart, D., Moreau, A. S., Canet, E., Kouatchet, A., Buell, K. G., Jaber, S., Argaud, L., Wallet, F., Pène, F., Demoule, A., & Azoulay, E. (2026). Individualized treatment effects of high flow nasal oxygen in immunocompromised patients. Intensive Care Medicine. https://doi.org/10.1007/s00134-026-08635-8

Vancouver

Maillard A, Métais M, Lemiale V, Mokart D, Moreau AS, Canet E, et al. Individualized treatment effects of high flow nasal oxygen in immunocompromised patients. Intensive Care Medicine. 2026. doi:10.1007/s00134-026-08635-8

BibTeX
@article{Maillard2026,
  author = {Maillard, Alexis and Métais, Mélanie and Lemiale, Virginie and Mokart, Djamel and Moreau, Anne-Sophie and Canet, Emmanuel and Kouatchet, Achille and Buell, Kevin G and Jaber, Samir and Argaud, Laurent and Wallet, Florent and Pène, Frédéric and Demoule, Alexandre and Azoulay, Elie},
  title = {Individualized treatment effects of high flow nasal oxygen in immunocompromised patients},
  journal = {Intensive Care Medicine},
  year = {2026},
  doi = {10.1007/s00134-026-08635-8}
}
Kostenlos starten →